Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and Gemcitabine for Stage IIIB/IV Non-Small Cell Lung Cancer
NCT00003762Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Feb 1999
- Primary completion
- Feb 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of docetaxel and gemcitabine in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Cancer and Leukemia Group B. Primary endpoint: Objective Response Rate at 5 years. Started Feb 1999; status: completed.
02
Drugs
docetaxelgemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00003762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003762.